Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

By: Sanofi Winthrop Industrie via GlobeNewswire

April 24, 2025 at 01:30 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Sanofi: strong Q1 performance and 2025 guidance confirmed

Paris, April 24, 2025

Q1 sales growth of 9.7% at CER¹ and business EPS² of €1.79

Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO
Dupixent sales were €3.5 billion, up 20.3%
Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasing
Research and Development expenses reached €1.8 billion, up 6.9%
Selling, general and administrative expenses were €2.2 billion, up 3.8%
Business EPS was €1.79, up 15.7% at CER and up 17.0% reported; IFRS EPS was €1.52

Pipeline continued to deliver

Six regulatory approvals across medicines in immunology, rare diseases, and oncology
Recent new data from the mid-stage pipeline unlocks late-stage studies in asthma and skin diseases, broadening and deepening the scope in immunology

Sustainability strategy

Updated sustainability strategy focuses on access to healthcare, environmental impact, and resilience of healthcare systems. 70% of the portfolio and >75% of the pipeline target diseases that are impacted by climate and environmental challenges

Capital allocation

The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q2³
Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager⁴

Guidance confirmed

In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER⁵. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)⁶
Sanofi intends to complete a share buyback program in 2025 of €5 billion of which 72% was already repurchased

Paul Hudson, Chief Executive Officer: “We had a strong start in 2025 with sales growth of 9.7%, benefiting from investments in innovation and a favorable base of comparison. Our focus on pipeline value delivered further growth for Sanofi with sales from launches of new medicines and vaccines growing by 46.5%. We obtained approval for Qfitlia (fitusiran), a new treatment for patients with hemophilia, one of three potential launches this year. ALTUVIIIO is continuing to gain market share and is on track to become our next blockbuster in the full year. Business EPS was €1.79, confirming the expected strong rebound in 2025.

Our redeployment of capital continued with significant progress on our share buyback program, the upcoming closing of the sale of a majority stake in Opella and the recent acquisition of a bispecific myeloid cell engager for deep B-cell depletion in immunology, strengthening our early pipeline and providing a potential treatment option in difficult-to-treat diseases like lupus.

We achieved significant advances in the pipeline with six approvals. We also delivered steady progress across many new medicines in respiratory diseases and dermatology, including clinically meaningful efficacy for amlitelimab in asthma, allowing us to enter phase 3 development to create future value for patients, society, and our company. Underpinned by the growth in sales and business EPS, we confirm our 2025 guidance with the knowledge of the external environment we have today.”

	Q1 2025	Change	Change at CER
IFRS net sales reported	€9,895m	+10.8%	+9.7%
IFRS net income reported	€1,872m	+65.2%	—
IFRS EPS reported	€1.52	+67.0%	—
Free cash flow⁷	€1,029m	—	—
Business operating income	€2,902m	+20.1%	+18.7 %
Business net income	€2,212m	+15.9%	+14.5 %
Business EPS	€1.79	+17.0%	+15.7%

Attachment

Press_Release

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	284.02	+0.00 (0.00%)
AAPL	303.42	+0.00 (0.00%)
AMD	484.64	+0.00 (0.00%)
BAC	62.48	+0.00 (0.00%)
GOOG	372.47	+0.00 (0.00%)
META	590.24	+0.00 (0.00%)
MSFT	487.65	+0.00 (0.00%)
NVDA	206.64	+0.00 (0.00%)
ORCL	141.85	+0.00 (0.00%)
TSLA	322.08	+0.00 (0.00%)